Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00147264

Recruitment Status : Completed

First Posted : September 7, 2005

Last Update Posted : December 14, 2016

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Boehringer Ingelheim

Canadian Institutes of Health Research (CIHR)

Heart and Stroke Foundation of Canada

Medtronic

Information provided by:

McMaster University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	January 2006
Actual Study Completion Date :	November 2006

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Chetty VT, Damjanovic S, Gerstein H, Singh N, Yusuf S, Anand SS, Sharma AM. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. Blood Press. 2014 Feb;23(1):54-60. doi: 10.3109/08037051.2013.791411. Epub 2013 Jun 3.

Kochan AM, Wolever TM, Chetty VT, Anand SS, Gerstein HC, Sharma AM. Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. J Nutr. 2012 Jan;142(1):27-32. doi: 10.3945/jn.111.146571. Epub 2011 Nov 16.

To Top